Evaluation of the Prognostic Value of Early Interim PET/CT for Prediction of Progression Free Survival of Patients With Aggressive B Cells Non Hodgkin Lymphoma
18 Years
70 Years
Both
Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse
Trial Information
Evaluation of the Prognostic Value of Early Interim PET/CT for Prediction of Progression Free Survival of Patients With Aggressive B Cells Non Hodgkin Lymphoma
Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing
regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of
chemotherapy to rule out disease progression . Currently a retrospective evaluation of
PET/CT as a predictive value for progression free survival and overall survival is evaluated
Inclusion Criteria:
- aggressive non-Hodgkin lymphoma b cells
- age 18-70
- bilirubin less then 2
- creatinine less then 2
- Pet/CT performed post 2 cycles
Exclusion Criteria:
- no PET/CT post 2 cycles performed
- bilirubin >2
- creatinine more then 2
- HIV positivity
Type of Study:
Observational
Study Design:
Observational Model: Cohort
Principal Investigator
Eldad J Dann, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
RAMBAM health care campus,Rappaport faculty of medicine Technion Israel Technical institute
Authority:
Israel: Israeli Health Ministry Pharmaceutical Administration
Study ID:
cc-NHL2615_CTIL
NCT ID:
NCT00498667
Start Date:
December 2006
Completion Date:
December 2011
Related Keywords:
- Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse
- PET/CT
- Aggressive non-Hodgkin Lymphoma
- Lymphoma
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
Name | Location |
|---|
